Randy P. Juhl is the Vice Chancellor for Research Conduct and Compliance for the University of Pittsburgh and professor of pharmaceutical sciences in the University's School of Pharmacy. He received an A.A. from Waldorf College in 1968 and a B.S., M.S. and Ph.D. in pharmacy from the University of Iowa in 1972, 1974 and 1976 respectively. His first academic appointment was at Ferris State University where he served as an assistant professor and director of the school's clinical pharmacy programs. In 1979 he moved to the University of Pittsburgh to serve as chair of the department of pharmacy practice. In 1986 he was named dean of the School of Pharmacy, a position he held for 16 years until 2002. During his tenure as dean, the school converted its entry level practitioner degree program from the Bachelor's level to the Pharm.D., instituted advanced practice residencies in conjunction with the University of Pittsburgh Medical Center and other partners, developed an innovative clinical scientist Ph.D. program and increased the school's endowment more than tenfold. The school also attained a top ten ranking among schools and colleges of pharmacy as measured by grant support from the NIH (currently #6).

In July of 2002 Dr. Juhl left the deanship to accept the invitation from Chancellor Mark Nordenberg to join the University's senior leadership as Vice Chancellor for Research Conduct and Compliance. His responsibilities as Vice Chancellor include the administrative oversight of the University's Institutional Review Board (IRB), the Institutional Animal Care and Use Committee (IACUC), the Radiation Safety Program, the Recombinant DNA Office and components of the University's conflict of interest reporting and monitoring functions.

Dr. Juhl's research included the effects of disease states and other conditions on the pharmacokinetics and pharmacodynamics of drugs. He has authored or co-authored over 70 manuscripts, abstracts and books on these and related topics.

Dr. Juhl served as President of the Academy of Pharmaceutical Research and Science in the American Pharmaceutical Association in 1992 - 1993. In 1992, he was asked to chair the newly created FDA advisory committee on non-prescription drugs. Dr. Juhl served as this committee's chair from 1992 to 1996. The committee is responsible for advising the FDA on a range of issues related to non-prescription drugs, including the Rx-to-OTC switch process. In 1998, Dr. Juhl was appointed chairman of the Pharmacy Compounding Advisory Committee for the FDA. This new advisory committee was created by the FDA Modernization Act of 1997 to serve as a public forum for the resolution of regulatory issues affecting pharmacy compounding.

Dr. Juhl has been honored as a distinguished alumnus of both Waldorf College (1994) and the University of Iowa College of Pharmacy (2000).

Currently Dr. Juhl consults for several companies and organizations that deal with self-medication and the Rx to OTC switch process and is a frequent speaker on a variety of FDA-related regulatory topics.